A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)
Details
Age
Adult
Locations
Cherry Creek Medical Center
CTRC Inpatient
Highlands Ranch Hospital
Lone Tree Medical Center
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Jennifer Diamond
Study ID
Protocol Number: 23-1469
More information available at ClinicalTrials.gov: NCT06112379
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers